Sodium‐glucose co‐transporter 2 inhibitors on weight change and cardiometabolic profiles in individuals with overweight or obesity and without diabetes: A meta‐analysis

Summary Several meta‐analyses have been conducted to evaluate the weight loss effect of sodium–glucose cotransporter 2 (SGLT‐2) inhibitors in patients with type 2 diabetes, whereas pooled analysis focusing on individuals without diabetes is lacking. The objective of this systematic review and meta‐analysis is to evaluate the effect of SGLT‐2 inhibitor monotherapy on weight change and cardiometabolic profiles. Multiple databases were searched for randomized controlled trials reporting weight change effect of SGLT‐2 inhibitor treatment compared with placebo for more than 12 weeks among individuals with overweight or obesity and without diabetes. A total of eight randomized controlled trials with 750 subjects were identified. SGLT‐2 monotherapy was associated with significant reduction in body weight of −2.32 kg, compared to −1.01 kg for placebo, giving a mean difference of −1.31 kg. Significant reductions in body mass index and fasting blood glucose were observed, but not for the changes in waist circumference, fat mass, blood pressure, and lipid profile compared with placebo. SGLT‐2 inhibitor monotherapy for 12 weeks or more can result in modest weight loss among people with overweight or obesity and without diabetes. Depending on pre‐existing comorbidities or risk factors, SGLT‐2 inhibitors can be considered adjuncts in the treatment of obesity.